MYLK3 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Bgt-226 Free Base (SCHEMBL146939)	1.00	1/20
Sch-900776 (SCHEMBL2408669)	1.00	1/20
Gsk-1070916 (SCHEMBL4305006)	1.00	1/20
Bgt-226 Free Base (SCHEMBL996046)	0.89	1/20
Bgt-226 Free Base (SCHEMBL996047)	0.89	1/20
SCHEMBL4305024	0.86	1/20
SCHEMBL928275	0.86	1/20
SCHEMBL4310001	0.85	1/20
SCHEMBL4308835	0.85	1/20
SCHEMBL4312311	0.85	1/20
SCHEMBL4314610	0.85	1/20
SCHEMBL928292	0.84	1/20
SCHEMBL4309223	0.84	1/20
SCHEMBL3502961	0.84	1/20
SCHEMBL4311597	0.84	1/20
SCHEMBL4305318	0.84	1/20
SCHEMBL3503253	0.83	1/20
SCHEMBL928009	0.82	1/20
SCHEMBL3503422	0.82	1/20
SCHEMBL4310134	0.81	1/20

Clinical trials — most relevant to MYLK3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem	PHASE2/PHASE3	COMPLETED
Cardiac REperfusion With Intralipid® at Reperfusion	PHASE2/PHASE3	UNKNOWN
Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy	PHASE2	RECRUITING
COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure	PHASE2	COMPLETED
A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy	PHASE2	RECRUITING
Evaluating MED2005 & Nitrostat Bioavailability	PHASE1	COMPLETED
Autologous Cultured Myoblasts (BioWhittaker) Transplanted Via Myocardial Injection	PHASE1	UNKNOWN
Genetic Analysis of African-Americans With High Blood Pressure	nan	COMPLETED
Transcutaneous Functional Magnetic Muscle Stimulation in Critically Ill	nan	UNKNOWN
Muscle Wasting in Cancer (MWIC)	nan	COMPLETED
Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms	nan	COMPLETED
Precision Medicine for Nociception, Sngception and Proprioception.	nan	RECRUITING
Nuclear Myosin VI - a Therapeutic Target in Breast Cancer	nan	UNKNOWN
Mapping of End Stage Renal Disease Genetic Susceptibility in African Americans by Admixture Linkage Disequilibrium	nan	COMPLETED
Signs and Symptoms Associated With Molecular Defects in Genetically Inherited Heart Disease	nan	COMPLETED
Phenotypic and Genotypic Identification and Characterization of MYH9-related Constitutional Thrombocytopenia	nan	COMPLETED
Study of Genotype and Phenotype Characterization in Duchenne Muscular Dystrophy With Small Mutations	nan	UNKNOWN
Pediatric Cardiomyopathy Mutation Analysis	nan	RECRUITING
Effect of Exercise on the Human Skeletal Muscle Phosphoproteome	nan	COMPLETED
B3 for NMD: Bench to Bedside and Back	nan	ENROLLING_BY_INVITATION
Muscle Tissue Bank for Muscular Dystrophy	nan	COMPLETED
Congenital Muscle Disease Study of Patient and Family Reported Medical Information	nan	RECRUITING
Biomarkers in the Diagnosis and Prognosis of NAFLD	nan	RECRUITING
Recurrent Acute Myocarditis Registry	nan	UNKNOWN
Effects of Whole Body Vibration and Resistance Exercise on Carotis Intima Media and Muscle Architecture in Hypertension	nan	COMPLETED
Maintenance of Muscle Mass in Older People: the Negative Impact of Statin Therapy	nan	COMPLETED
Phenotype - Genotype Correlation in a Sample of Egyptian Patients With Congenital Myopathies and Congenital Muscular Dystrophies	nan	RECRUITING
Effect of a Targeted Notification and Clinical Support Pathway on Individuals With Left Ventricular Hypertrophy	nan	COMPLETED
Transcutaneous Electrical Diaphragmatic Stimulation in Critically Ill Elderly Patients	nan	UNKNOWN
Exploring Novel Biomarkers of ICU-AW in Mechanically Ventilated Children at the Molecular Level	nan	ENROLLING_BY_INVITATION

Related proteins — ESM-2 sequence neighbours (a MYLK3 binder may also engage these)

Protein	Name	Similarity
Q5RDG7	—	1.000	Q5RDG7 →
Q3UIZ8	—	0.999	Q3UIZ8 →
Q8BLR5	—	0.992	Q8BLR5 →
E9PT87	—	0.991	E9PT87 →
Q0KK55	—	0.990	Q0KK55 →
P20689	—	0.990	P20689 →
Q8BWQ5	—	0.990	Q8BWQ5 →
Q8VDG6	—	0.989	Q8VDG6 →
Q8CB87	—	0.989	Q8CB87 →
Q8NDX1	—	0.988	Q8NDX1 →
Q9WUL6	—	0.988	Q9WUL6 →
Q9Z0E3	—	0.988	Q9Z0E3 →
Q8BWG4	—	0.988	Q8BWG4 →
Q9Y6A5	—	0.988	Q9Y6A5 →
Q8NHY3	—	0.987	Q8NHY3 →
Q7Z6I6	—	0.987	Q7Z6I6 →
Q60700	—	0.987	Q60700 →
Q7Z6P3	—	0.987	Q7Z6P3 →
A6X8Z5	—	0.987	A6X8Z5 →
Q8BZW2	—	0.987	Q8BZW2 →
Q9H7P9	—	0.987	Q9H7P9 →
Q3UJD6	—	0.987	Q3UJD6 →
MAP3K14	Mitogen-activated protein kinase kinase kinase 14	0.987	landscape →
Q80UE6	—	0.986	Q80UE6 →
A6NJZ7	—	0.986	A6NJZ7 →
A0A8I3PMN2	—	0.986	A0A8I3PMN2 →
O95201	—	0.986	O95201 →
A6NNM3	—	0.986	A6NNM3 →
USP19	Ubiquitin carboxyl-terminal hydrolase 19	0.986	landscape →
Q6PCN3	—	0.986	Q6PCN3 →